Participated · Seed · Jan 2026

Enodia Therapeutics is building a small-molecule drug discovery platform that selectively modulates the SEC61 translocon, enabling degradation of secreted and membrane proteins before they leave the endoplasmic reticulum. The approach blends a tailored library of signal-peptide cell lines, proteomics-based secretome analysis and machine-learning models to achieve unprecedented selectivity in targeted protein degradation. Originating from research at the Institut Pasteur and incubated by Argobio Studio, the company is initially pursuing inflammatory and autoimmune disease programs while exploring applications in oncology and viral infections. Management intends to advance the lead program to preclinical candidate selection within the next twelve months, marking a key value inflection point. The platform leverages several families of well-characterized inhibitors, offering the potential to unlock previously undruggable targets. Enodia’s strategy emphasizes repeated translation of complex SEC61 biology into differentiated drug candidates and broad partnering potential. The recent seed financing provides the capital to validate the platform and expand the early pipeline. No commercial revenue or clinical-stage assets have been disclosed to date.

Participated · Series B · Jan 2026

EpiBiologics is a San Mateo–based biotechnology company pioneering the degradation of disease-driving extracellular membrane and soluble proteins via its proprietary EpiTAC bispecific antibody platform. The company’s lead candidate, EPI-326, is designed to degrade all oncogenic forms of EGFR in a tumor-selective manner, aiming to overcome safety and resistance limitations of current EGFR therapies. Preclinical data show strong, durable efficacy with favorable safety and pharmacokinetic profiles, supporting both monotherapy and combination use across multiple cancer types. EpiBiologics plans to commence a first-in-human trial of EPI-326 in early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma. Proceeds from its recent financing will also expand a broader pipeline in oncology and immunology while bolstering internal capabilities. The company recently strengthened its leadership team by hiring Eric Humke, M.D., Ph.D., as Chief Medical Officer and Aaron Mishel as Chief Financial Officer, and added several industry leaders to its Board.

Participated · Series B · Jan 2026

Nocion Therapeutics is advancing taplucainium (formerly NTX-1175), a first-in-class, once-daily dry-powder inhaled charged sodium channel blocker (CSCB) that selectively silences activated airway nociceptors while minimizing systemic exposure. The company positions taplucainium as a potentially best-in-class therapy for the roughly nine million U.S. patients suffering from refractory or unexplained chronic cough, a field with no new FDA-approved drugs in 65 years. Taplucainium is currently being evaluated in the ASPIRE Phase 2b trial enrolling patients across the U.S., Canada, the U.K., and Europe, with topline data expected in mid-2026. Proceeds from the latest financing will fund trial completion, an End-of-Phase 2 meeting, and CMC work in preparation for late-stage studies, giving Nocion an operating runway through 2027. Beyond cough, the company’s CSCB platform may be applied to other conditions involving activated sensory neurons such as itch and pain. Nocion is headquartered in Watertown, Massachusetts, and was founded on intellectual property licensed from Harvard University and Boston Children’s Hospital. To date, the company has raised $93 million in Series B funding, including the recent extension.

Led · Series A · Nov 2025

AI Proteins has built an AI-enabled discovery platform that designs and optimizes de novo miniproteins, giving the company precise control over molecular function, stability, and pharmacology. The platform’s industrialized design-build-test cycle has already produced molecules against more than 150 targets and delivered multiple in-vivo proof-of-concepts. In December 2024 the company entered a research collaboration and option agreement with Bristol Myers Squibb worth up to $400 million, validating commercial interest in its technology. Beyond internal drug programs, the modular miniproteins can be applied to diagnostics, agriculture and research reagents. To scale efficiently, AI Proteins is adopting a hub-and-spoke LLC structure that spins individual programs into subsidiaries while preserving the core platform. The new capital will bolster platform expansion, data generation, and advancement of lead therapeutic candidates toward IND-enabling studies. The company’s investors believe the approach could usher in a new class of protein medicines that outperform traditional antibodies.

Participated · Series A · Aug 2025

Sensorium Therapeutics develops brain and mental health treatments derived from natural products and driven by mechanistic neuroscience. Its proprietary SensAI platform integrates artificial intelligence, chemistry, and neuroscience to mine more than 50 million curated relationships across biology, pharmacology, clinical outcomes, and human experience. SensAI has produced three differentiated programs in under three years, led by SNTX-2643, a first-in-class precision serotonin modulator for anxiety. The company recently received FDA clearance of an IND for SNTX-2643, enabling first-in-human dosing beginning in Q3 2025. Sensorium describes SNTX-2643 as re-engineered from a natural product to enable rapid onset, reduce off-target side effects, and avoid sedation versus benzodiazepine-like drugs. Sensorium has built an IP estate extending into the 2040s and has made executive leadership changes concurrent with its clinical advancement. Sensorium Therapeutics is a Boston-based biotechnology company developing nature-inspired psychoactive medicines for mental health. The company leverages medicinal chemistry, neuroscience, and machine learning to discover and optimize compounds. Its initial asset is SENS-01 and it operates the Biodynamic Discovery Platform (BDP), a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as novel therapeutics. Sensorium closed a $30 million Series A financing to advance SENS-01 and further develop the BDP. The company aims to use the proceeds to move those programs forward.